Aurobindo Pharma subsidiary Eugia Pharma Specialities has launched Pomalidomide Capsules, in different strengths, in the U.S. market.
Eugia was one of the first-to-file (FTF) ANDA applicants for the product and will manufacture the product, which is used to treat relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma, at its Unit-I.
The product is a generic equivalent of BMS Pharmaceuticals Corp’s Pomalyst Capsules. In the U.S. for the twelve months ending January 2026, Pomalidomide capsules had an estimated market size of around $ 3.3 billion, Aurobindo Pharma said citing IQVIA MAT data.
Published – March 04, 2026 08:03 pm IST
Source: https://www.thehindu.com/business/aurobindo-pharma-subsidiary-launches-generic-of-cancer-drug/article70702925.ece
